Companies covered: Bayer AG (ADR) (OTCMKTS:BAYRY), Axovant Sciences Ltd. (NASDAQ:AXGT), AveXis Inc (NASDAQ:AVXS), uniQure N.V. (NASDAQ:QURE), Spark Therapeutics, Inc. (NASDAQ:ONCE), Ophthotech Corporation (NASDAQ:OPHT), Valeant Pharmaceuticals International, Inc. (NYSE:VRX), Novartis AG (NYSE:NVS), The Medicines Company (NASDAQ:MDCO), GlaxoSmithKline PLC (NYSE:GSK), AstraZeneca PLC (NASDAQ:AZN), Novo Nordisk A/S (NYSE:NVO), Roche Holdings Ltd. (ADR) (OTCMKTS:RHHBY), Sanofi (NYSE:SNY), Pfizer, Inc. (NYSE:PFE), Regenxbio Inc (NASDAQ:RGNX), Endo International plc (NASDAQ:ENDP), Cipher Pharmaceuticals Inc. (NASDAQ:CPHR), NUVO PHARMACEUTICA COM NPV (OTCMKTS:NRIFF), Horizon Pharma plc (NASDAQ:HZNP), Retrophin, Inc. (NASDAQ:RTRX), Cempra, Inc. (NASDAQ:CEMP), Omeros Corporation (NASDAQ:OMER), Sarepta Therapeutics, Inc. (NASDAQ:SRPT), T2 Biosystems, Inc. (NASDAQ:TTOO), Kadmon Holdings Inc (NYSE:KDMN), American International Group, Inc. (NYSE:AIG), Amgen Inc. (NASDAQ:AMGN), Biogen Inc. (NASDAQ:BIIB), Celgene Corporation (NASDAQ:CELG), Sophiris Bio, Inc. (NASDAQ:SPHS), Mateon Therapeutics, Inc. (NASDAQ:MATN), PharmaCyte Biotech, Inc. (OTCMKTS:PMCB), Biostage, Inc. (NASDAQ:BSTG), Ignyta, Inc. (NASDAQ:RXDX), Asterias Biotherapeutics, Inc. (AMEX:AST), Hemispherx Biopharma, Inc. (NYSEMKT:HEB), pSivida Corp. (NASDAQ:PSDV), Aytu BioScience, Inc. (OTCMKTS:AYTU), Apricus Biosciences, Inc (NASDAQ:APRI)
